| Similar Articles |
|---|
 |
Pharmaceutical Executive
August 1, 2011
Ben Comer |
Is the 'Emerging Market' a Dated Concept? When it comes to the emerging markets, executing a few key elements of success are more important than ever.   |
Pharmaceutical Executive
September 1, 2013
William Looney |
High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets. |
Pharmaceutical Executive
November 1, 2008 |
No Ordinary Joe It's been a year since consumer marketing master Joe Jimenez took over the top spot at Novartis Pharma. How's he faring? |
Pharmaceutical Executive
July 1, 2013
Looney et al. |
Pharm Exec's 2013 Emerging Pharma Leaders Meet the Emerging Pharma Leaders of 2013. These 15 trend setters represent the future of an industry that knows it must change: the question is how, and to what? |
Pharmaceutical Executive
October 1, 2011 |
Pharma Futures: The Next 30 Years Success for the next 30 years in the pharmaceutical industry depends significantly on navigating the myths and mental traps of emerging market strategy. |
Pharmaceutical Executive
January 21, 2014
William Looney |
Russia's Bet on Biopharma Can innovation trump ideology? Russia faces a stark choice in betting on the visible hand of government in promoting a "world class" biopharmaceutical sector |
Pharmaceutical Executive
July 1, 2012 |
Emerging Pharma Leaders 2012 Meet 2012's Emerging Pharma Leaders. Can these 15 global trend setters set the mark on their time in history by doing better with less while tapping new opportunities from science and technology to build competitive scale? |
Pharmaceutical Executive
June 1, 2011 |
Emerging Pharma Leaders 2011 Meet 2011's Emerging Pharma Leaders. Can these 30 trendsetters build competitive scale from scarcity? |
Pharmaceutical Executive
September 1, 2012
Thomas Baker |
The Big Sell: Biologics In Emerging Markets High priced biologics may have a bright future in emerging markets, but winning access in the short term will be a hard sell without a tailored clinical profile, a compelling local message, and direct government support. |
Pharmaceutical Executive
February 1, 2012 |
Brazil Report: A Bold Player Blooms Brazil was the last country to enter the fiscal crisis, but also the first to exit. And with a burgeoning middle class and a staunch commitment to national development, its pharmaceutical future is now. |
Pharmaceutical Executive
January 1, 2012
William Looney |
The Well of Engagement We sometimes forget that the business of healthcare is also the source of a huge opportunity: improving the human condition. |
Pharmaceutical Executive
February 1, 2013 |
Country Report: Australia In some ways the Australian medicines industry is going through the same restructuring and challenges as the industry is globally. |
Pharmaceutical Executive
August 1, 2008 |
Harbingers of Change The pharmaceutical industry is changing. Here are eight seminal events that describe how. |
Pharmaceutical Executive
October 1, 2005 |
Successful Alliances: Novartis and Idenix Share the Secrets of Success Novartis Pharma AG CEO Thomas Ebeling and Idenix founder, CEO, and chairman Jean-Pierre Sommadossi discuss the mutual benefits and challenges of maintaining a successful partnership. |
Pharmaceutical Executive
September 1, 2012
Stan Bernard |
The Payer C Change: From Customers to Competitors "Payers have evolved to become powerful global contenders with pharma for increasingly limited funding of drug budgets." Understanding why and how this payer shift to dominance occurred is critical for pharmaceutical professionals in adjusting their business model. |
Pharmaceutical Executive
October 1, 2011
Daniel Vasella |
Heart of Success: Patient-Centric R&D Drug discovery must remain a core competency of industry. The future success of individual companies will be tightly linked to success in R&D. |
Chemistry World
April 25, 2014
Andy Extance |
$25bn-plus trade sharpens pharma giants' focus Three leading pharmaceutical firms are set to exchange business segments valued at over $25 billion, in deals affecting at least 14,000 employees. |
BusinessWeek
January 7, 2010
Capell & Doherty |
What Novartis Sees in Eye Care Novartis CEO Dan Vasella's $50 billion bet on Alcon could help insulate it from the vagaries of the drug business. |
Pharmaceutical Executive
April 1, 2011 |
Winning Beyond the Molecule It can take both a clinical and non-clinical approach to win the differentiation competition. |
The Motley Fool
April 21, 2005
Stephen D. Simpson |
Novartis' Triple Threat The Swiss drug giant boasts strong franchises in generics, cardiology, and oncology. It's hard not to think of Novartis as one of the highest-quality options in the pharmaceutical investing space. |
The Motley Fool
October 23, 2006
Brian Lawler |
No Slowing Novartis The Swiss pharmaceutical company shows strength in nearly all its divisions. Novartis looks like a good investment for risk-adverse investors searching for a large-cap pharma stock. |
The Motley Fool
July 28, 2011
Melly Alazraki |
J&J or Novartis? Novartis' businesses are an investor's delight; J&J's improving but isn't there yet. |
Chemistry World
February 15, 2007
Victoria Gill |
Novartis Contests India's Patent Law Swiss pharmaceutical company Novartis has accused the Indian government of failing to comply with WTO rules after it refused to grant the company a patent on its cancer drug Glivec. |
Bio-IT World
November 2005
Mark D. Uehling |
The Unstoppable Swiss At a time when other pharmaceutical giants struggle to justify pediatric uses of their medicines, or to defend themselves against thousands of lawsuits, Novartis has one of the safest and strongest pipelines in the industry. |
Pharmaceutical Executive
February 1, 2011
Jennifer Ringler |
Skipping the Needle: Pharm Exec's Brand of the Year Novartis' Gilenya is a step forward in treating Multiple Sclerosis. But generating increased compliance is another story |
BusinessWeek
June 11, 2009
Kerry Capell |
Novartis: Radically Remaking Its Drug Business CEO Dan Vasella's growth mantra for Novartis is follow the science, not the financials. |
Pharmaceutical Executive
November 1, 2006
Joanna Breitstein |
Back Page: The Case for Diversity Variety is the spice of life - and the future of Big Pharma. |
Pharmaceutical Executive
July 3, 2007 |
Thought Leader: Connected Markets, Rob Dhoble It used to be that pharma companies had one marketing strategy for the US and other developed nations, a second strategy for emerging countries, and a third, mostly focused around access, for the developing world. But in a global environment, that doesn't work. |
The Motley Fool
January 20, 2005
Stephen D. Simpson |
Novartis Posts a Swiss Miss The Swiss drug giant has a strong pipeline, but moderate growth and high valuation suggest little room for error. |
The Motley Fool
September 1, 2005
Stephen D. Simpson |
Novartis Keeps Gorging Offering to buy the remainder of Chiron for $4.5 billion may up this company's execution risk over the next few quarters. Investors, take note. |
BusinessWeek
April 18, 2005
Manjeet Kripalani |
India: Bigger Pharma Tougher patent protection laws are spurring rapid growth in new drug research across India. |
Pharmaceutical Executive
October 1, 2011
William Looney |
The Gathering Profiles of 30 of the pharmaceutical industry's key influences of the last three decades. |
The Motley Fool
January 27, 2010
Brian Orelli |
Nice, Novartis, Very Nice CEO Daniel Vasella leaves on a high note. |
Chemistry World
August 6, 2007
Victoria Gill |
Novartis Loses Indian Patent Law Case Swiss drug firm Novartis has lost its legal case against the Indian government, who it had accused of 'unconstitutional' patent law practices. The ruling sets an important precedent that will cheer the flourishing generics market in the country. |
The Motley Fool
July 15, 2005
Stephen D. Simpson |
Novartis' Over-the-Counter Tonic Novartis' latest purchase suggests a commitment to making itself a well-rounded pharma giant. Future margins may not be as high as they once were, but if the company can produce a lot more cash flow, investors won't mind a bit. |
BusinessWeek
February 4, 2010
Dermot Doherty |
The New Man at Novartis CEO Joe Jimenez says his consumer-products background, with stints at Clorox and Heinz, will be a booster for the drugmaker. |
Registered Rep.
May 10, 2012
Jennifer Duell Popovec |
Emerging Real Estate in Emerging Markets While most investors lack a deep understanding of emerging markets overall, most of them know enough to be excited about these countries and the investment opportunities they offer. |
The Motley Fool
October 22, 2007
Brian Lawler |
No Catastrophes at Novartis Novartis stays on track with its third-quarter results. Investors, take note. |
The Motley Fool
December 19, 2006
Brian Gorman |
Novartis Cuts in Line at the Drugstore Consolidation in pharmacy benefits management may leave Novartis most resistant to pricing pressure. Investors, take note. |
The Motley Fool
June 6, 2008
Brian Lawler |
Nothing Can Stop Novartis! Swiss pharmaceutical giant Novartis has bucketloads of cash, and apparently, it isn't afraid to use them. |
Pharmaceutical Executive
May 1, 2011
Cacciotti & Clinton |
12th Annual Pharm Exec 50 Pharm Exec's annual run-down of the world's biggest pharma companies. |
Chemistry World
November 6, 2013
Laura Howes |
Novartis to shut Horsham site Last year, the firm slammed the UK for the high cost of conducting clinical trials in the country, warning that business would leave unless more incentives were introduced to encourage firms to carry out R&D. |
Bio-IT World
July 14, 2004
Davies & Russell |
The Sweet Hereafter Novartis' stunning new research home in a former candy factory is but one ingredient in a bold new recipe for success that embraces leadership, culture, science, and technology. |
The Motley Fool
October 23, 2009
Brian Orelli |
Swine Flu Doesn't Need to Save Novartis The company is looking healthy all on its own. |
The Motley Fool
November 6, 2006
Brian Gorman |
Novartis' China Gambit Novartis probably won't get any near-term dividend from its China investment, but the nation is too big to ignore. Investors, take note. |
Pharmaceutical Executive
May 1, 2012 |
Pharm Exec 50: Growth from the Bottom Up More consolidation didn't boost pharmaceutical sales at the top, but a handful of nimble newcomers posted impressive growth on the other end of the curve. |
Financial Advisor
July 2009
Jeff Schlegel |
Rebuilding With BRICs The Big Four of emerging markets are back in favor. |
Chemistry World
September 10, 2015
Katrina Megget |
Merger fever sweeps pharma Cheap financing, among other factors, is allowing companies to stock their drug pipelines through acquisitions |
Pharmaceutical Executive
June 9, 2014
Cliff Kalb |
The Urge to Merge Deal making lessons for pharmaceutical companies from history's storyboard. |
The Motley Fool
October 21, 2008
Brian Orelli |
Novartis Is Taking the Road Less Traveled Diversification should pay off for this pharma giant. |
